Jeffrey Berinstein, MD, MSc
Department of Internal Medicine, Division of Gastroenterology and Hepatology
1500 E. Medical Center Dr.
Ann Arbor, MI
Manage Your Profile
About
I am an NIH-funded clinician-scientist and Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of Michigan. My clinical and research program focuses on improving the care of patients with inflammatory bowel disease, particularly those with acute severe ulcerative colitis (ASUC(. My work integrates clinical investigation, pragmatic and adaptive clinical trial design, prediction modeling, and implementation of evidence-based care pathways to improve treatment selection and clinical outcomes.
Qualifications
-
Clinical Trials Academy IIUniversity of Michigan, Ann Arbor, United States
2024 - 2025
Other
-
Clinical Trials Academy IUniversity of Michigan, Ann Arbor, United States
2022 - 2022
Other
-
FellowUniversity of Michigan–Ann Arbor, Gastroenterology and Hepatology, Ann Arbor, United States
2018 - 2021
Postdoctoral Fellowship
-
Chief Fellow University of Michigan Health System, Ann Arbor, MichiganUniversity of Michigan Health System, Internal Medicine- Gastroenterology, Ann Arbor, MI, United States
2020 - 2021
Chief Resident
-
ResidentUniversity of Michigan, Internal Medicine, Ann Arbor, MI, United States
2015 - 2018
Residency
-
MSc, Health and Healthcare ResearchUniversity of Michigan–Ann Arbor, Ann Arbor, United States
2018 - 2019
-
MDTechnion – Israel Institute of Technology, Haifa, Israel
2011 - 2015
-
BSc, Molecular Biology, HonorsMcMaster University, Hamilton, Canada
2006 - 2010
Center Memberships
-
Center MemberInstitute for Healthcare Policy and Innovation
Research Overview
I am interested in employing novel research methods to optimize care delivery for patients with inflammatory bowel disease. Specifically, my research uses machine learning and prediction modeling, adaptive interventions, and innovative clinical trial designs to develop evidence-based, patient-tailored treatment pathways for patients with acute severe ulcerative colitis. My broader goal is to improve treatment selection, identify patients at risk for poor outcomes earlier in their disease course, and translate evidence into scalable clinical care pathways.
Recent Publications
-
Berinstein J. 2026 Sep 18;PresentationInflammatory Bowel Disease Therapy Optimization
-
Berinstein J. 2026 Jul 16;PresentationThe Clock Is Ticking: Optimal Strategies to Reduce Colectomy in the Hospitalized Patient With Acute Severe Ulcerative Colitis
-
Berinstein J. 2026 Jul 16;PresentationInpatient IBD Management
-
Berinstein J. 2026 Jul 16;PresentationAcute Severe Ulcerative Colitis: 6 Fundamental Principals to Lower Colectomy
-
Berinstein J. 2026 Jul 16;PresentationEndoscopic Evaluation and Treatment of IBD
-
Goyal MK, Dutta P, Choy MC, Berinstein JA, Hassan SA, Sharma V, Ahuja V, Berinstein E, Li Wai Suen CFD, Higgins PDR, Con D, Cruz PD, Bishu S. Inflamm Bowel Dis, 2026 Jul 1; 32 (7): 1344 - 1353.Journal ArticleRethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.
DOI:10.1093/ibd/izag042 PMID: 42030468 -
Herran R, Wilcox S, Hodish G, Hassan SA, Mertens H, Almario CV, Gu P, Kayal M, Cohen-Mekelburg S, Regal RE, Bishu S, Siegel CA, DeJonckheere M, Higgins PDR, Berinstein JA. Dig Dis Sci, 2026 Jun 24;Journal ArticleNavigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-Making.
DOI:10.1007/s10620-026-10046-0 PMID: 42340521 -
Abdul Rehman K, Us Sehar N, Akram U, Fatima E, Ahsan S, Ahmed SZ, Faizan A, Javid S, Hassan SA, Berinstein JA, Barrett TA. Inflamm Bowel Dis, 2026 Jun 9;Journal ArticleClinical significance of isolated periappendiceal red patch in ulcerative colitis: A systematic review, meta-analysis, and meta-regression.
DOI:10.1093/ibd/izag092 PMID: 42262727
Featured News & Stories